Scripps Team Explores 'Practical' Considerations of Sequencing for Oncology Patients | GenomeWeb

By Bernadette Toner

Researchers at the Scripps Translational Science Institute are investigating a range of technical issues involved in using next-generation sequencing to help guide therapy for cancer patients — including the pros and cons of exome sequencing over whole-genome sequencing, as well as the impact of tumor heterogeneity on sequencing results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.